Ascendis Pharma A/S
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 14
- Market Cap
- $7.9B
- Introduction
Ascendant Resources Inc is a mining company. The company is engaged in evaluating resource opportunities. The Company’s sole investment and exploration activities are in the Lagoa Salgada Project in Portugal. It is focused on its own producing El Mochito zinc, silver and lead mine. The El Mochito mine is located in northwestern Honduras. The underground oper...
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 24
- Registration Number
- NCT06732895
- Locations
- 🇩🇰
Ascendis Investigational Site, Copenhagen, Denmark
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia
- Conditions
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05246033
- Locations
- 🇨🇳
Ascendis Pharma Investigational Site, Wuhan, China
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 57
- Registration Number
- NCT04085523
- Locations
- 🇵🇹
Ascendis Pharma Investigational Site, Coimbra, Portugal
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 59
- Registration Number
- NCT04009291
- Locations
- 🇳🇴
Ascendis Pharma Investigational Site, Oslo, Norway
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
- Conditions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 260
- Registration Number
- NCT03875534
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, London, United Kingdom
A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 20
- Registration Number
- NCT03803163
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 298
- Registration Number
- NCT03344458
- Locations
- 🇺🇦
Ascendis Pharma Investigational Site, Odesa, Ukraine
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
- Conditions
- Interventions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 53
- Registration Number
- NCT01947907
- Locations
- 🇺🇦
Kharkiv National Medical University, Kharkiv, Ukraine
🇺🇦Institute of Endocrinology and Metabolism, Kiev, Ukraine
🇺🇦Donetsk Regional Children Clinical Hospital, Donetsk, Ukraine
A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 37
- Registration Number
- NCT01247675
- Locations
- 🇩🇪
Charité University Hospital Berlin, Berlin, Germany
🇩🇰Aarhus University Hospital, Aarhus, Denmark
🇸🇪Karolinska University Hospital, Stockholm, Sweden
Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)
- Conditions
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 44
- Registration Number
- NCT01010425